Peterson L A, Thomson N M, Crankshaw D L, Donaldson E E, Kenney P J
Division of Environmental and Occupational Health and Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Cancer Res. 2001 Aug 1;61(15):5757-63.
The tobacco-specific nitrosamine, 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone, is activated to lung DNA methylating and pyridyloxobutylating intermediates. It is likely that both pathways play a role in lung tumor initiation by this nitrosamine. Previous studies indicated that O(6)-methylguanine (O(6)-mG) persistence is critical for lung tumor formation in A/J mice. The model pyridyloxobutylating agent, 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKOAc), enhanced the tumorigenic activity of a model methylating agent, acetoxymethylmethylnitrosamine (AMMN), presumably by increasing O(6)-mG persistence in lung DNA. We have been testing the hypothesis that the pyridyloxobutylation pathway increases the mutagenic activity of the DNA methylation pathway by preventing the repair of O(6)-mG by O(6)-alkylguanine-DNA alkyltransferase (AGT). In this study, we report that NNKOAc depletes AGT in lungs but not livers of A/J mice. The consequences of AGT depletion by NNKOAc were then compared with those observed with a known AGT inhibitor, O(6)-benzylguanine (O(6)-bG). NNKOAc and O(6)-bG had similar effects on the levels of AMMN-derived O(6)-mG at 4 and 96 h postinjection. This increase in O(6)-mG levels correlated to increased lung tumor multiplicity in animals simultaneously treated with AMMN (0.75 or 1 micromol) and NNKOAc or O(6)-bG. Only NNKOAc significantly increased lung tumor multiplicity at doses of 0.25 or 0.5 micromol AMMN. The results from these studies indicate that the pyridyloxobutylating agent, NNKOAc, can influence the tumorigenic activity of methylating agents in two ways. At low AMMN doses, the increase in tumor multiplicity is dominated by the additive tumorigenic properties of AMMN and NNKOAc. At higher AMMN doses, NNKOAc appears to enhance the tumorigenic activity of AMMN through enhanced depletion of the repair protein, AGT, leading to increased O(6)-mG persistence. It is likely that similar interactions are important for the organospecific effects of 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone.
烟草特有的亚硝胺,4-(甲基亚硝基氨基)-1-(3-吡啶基)-1-丁酮,可被激活生成肺DNA甲基化和吡啶氧基丁基化中间体。这两条途径可能在该亚硝胺引发肺癌的过程中都发挥作用。先前的研究表明,O(6)-甲基鸟嘌呤(O(6)-mG)的持续存在对A/J小鼠的肺癌形成至关重要。模型吡啶氧基丁基化剂4-(乙酰氧基甲基亚硝基氨基)-1-(3-吡啶基)-1-丁酮(NNKOAc)增强了模型甲基化剂乙酰氧基甲基甲基亚硝胺(AMMN)的致瘤活性,推测是通过增加肺DNA中O(6)-mG的持续存在来实现的。我们一直在验证这样一个假设:吡啶氧基丁基化途径通过阻止O(6)-烷基鸟嘌呤-DNA烷基转移酶(AGT)对O(6)-mG的修复,增加了DNA甲基化途径的诱变活性。在本研究中,我们报告NNKOAc可使A/J小鼠肺中的AGT减少,但肝脏中的AGT不受影响。然后将NNKOAc导致的AGT减少的后果与已知的AGT抑制剂O(6)-苄基鸟嘌呤(O(6)-bG)所观察到的后果进行比较。在注射后4小时和96小时,NNKOAc和O(6)-bG对AMMN衍生的O(6)-mG水平有相似的影响。在用AMMN(0.75或1微摩尔)与NNKOAc或O(6)-bG同时处理的动物中,O(6)-mG水平的这种升高与肺肿瘤多重性增加相关。只有NNKOAc在0.25或0.5微摩尔AMMN剂量下显著增加了肺肿瘤多重性。这些研究结果表明,吡啶氧基丁基化剂NNKOAc可以通过两种方式影响甲基化剂的致瘤活性。在低AMMN剂量下,肿瘤多重性的增加主要由AMMN和NNKOAc的相加致瘤特性主导。在较高AMMN剂量下,NNKOAc似乎通过增强对修复蛋白AGT的消耗来增强AMMN 的致瘤活性,导致O(6)-mG持续存在增加。4-(甲基亚硝基氨基)-1-(3-吡啶基)-1-丁酮的器官特异性效应可能也存在类似的相互作用。